Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer.

ABSTRACT:

Background

Immunotherapy using dendritic cell (DC) vaccine has the potential to overcome the bottleneck of cancer therapy.

Methods

We engineered Lewis lung cancer cells (LLCs) and bone marrow-derived DCs to express tumor-associated antigen (TAA) ovalbumin (OVA) via lentiviral vector plasmid encoding OVA gene. We then tested the antitumor effect of modified DCs both in vitro and in vivo.

Results

The results demonstrated that in vitro modified DCs could dramatically enhance T-cell proliferation (P<.01) and killing of LLCs than control groups (P<.05). Moreover, modified DCs could reduce tumor size and prolong the survival of LLC tumor-bearing mice than control groups (P<.01 and P<.01, respectively). Mechanistically, modified DCs demonstrated enhanced homing to T-cell-ric

SUBMITTER: Jiang T 

PROVIDER: S-EPMC5266489 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature